Tata Memorial Hospital Team Presents Biocon’s Nimotuzumab Study Results at ASCO Annual Meeting 2018

  • Posted by: Biocon Biologics

Mylan and Biocon to Present New Data at the American Society of Clinical Oncology (ASCO) Annual Meeting Reinforcing the Efficacy, Safety and Immunogenicity of Ogivri™, the first biosimilar for Herceptin®, approved by US FDA

  • Posted by: Biocon Biologics

Biocon Update on Insulin Glargine

  • Posted by: Biocon Biologics

Biocon Q4FY18 Revenue Rs 1,237 Cr, Up 27%; EBITDA Up 30% at Rs 300 Cr; Net Profit Up 2% at Rs 130 Cr

  • Posted by: Biocon Biologics

Kiran Mazumdar-Shaw #1 Business Captain in ‘The Medicine Maker 2018 Power List’

  • Posted by: Biocon Biologics

Mylan and Biocon seek to accelerate introduction of Adalimumab biosimilar in EU

  • Posted by: Biocon Biologics

Mylan and Biocon Receive Approvals from the European Commission and TGA, Australia for Semglee™ Biosimilar Insulin Glargine

  • Posted by: Biocon Biologics

Update on Company Statement on US-FDA Inspection at Biocon Malaysia

  • Posted by: Biocon Biologics

Company Statement on US-FDA Inspection at Biocon Malaysia

  • Posted by: Biocon Biologics

Mylan and Biocon Receive Positive CHMP Opinion for Semglee™, Biosimilar Insulin Glargine

  • Posted by: Biocon Biologics